31 – 40 of 53
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
(
- Contribution to journal › Article
- 2018
-
Mark
FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
(
- Contribution to journal › Article
-
Mark
Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays
(
- Contribution to journal › Article
-
Mark
Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
(
- Contribution to journal › Article
-
Mark
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
(
- Contribution to journal › Article
-
Mark
Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases
(
- Contribution to journal › Article
- 2017
-
Mark
Molecular classification of urothelial carcinoma : global mRNA classification versus tumour-cell phenotype classification
(
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
(
- Contribution to journal › Article